| Literature DB >> 25910206 |
Pradeep Reddy1, Alejandro Ocampo1, Keiichiro Suzuki1, Jinping Luo1, Sandra R Bacman2, Sion L Williams2, Atsushi Sugawara1, Daiji Okamura1, Yuji Tsunekawa3, Jun Wu1, David Lam1, Xiong Xiong4, Nuria Montserrat5, Concepcion Rodriguez Esteban1, Guang-Hui Liu6, Ignacio Sancho-Martinez1, Dolors Manau7, Salva Civico7, Francesc Cardellach8, Maria Del Mar O'Callaghan9, Jaime Campistol9, Huimin Zhao4, Josep M Campistol10, Carlos T Moraes11, Juan Carlos Izpisua Belmonte12.
Abstract
Mitochondrial diseases include a group of maternally inherited genetic disorders caused by mutations in mtDNA. In most of these patients, mutated mtDNA coexists with wild-type mtDNA, a situation known as mtDNA heteroplasmy. Here, we report on a strategy toward preventing germline transmission of mitochondrial diseases by inducing mtDNA heteroplasmy shift through the selective elimination of mutated mtDNA. As a proof of concept, we took advantage of NZB/BALB heteroplasmic mice, which contain two mtDNA haplotypes, BALB and NZB, and selectively prevented their germline transmission using either mitochondria-targeted restriction endonucleases or TALENs. In addition, we successfully reduced human mutated mtDNA levels responsible for Leber's hereditary optic neuropathy (LHOND), and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in mammalian oocytes using mitochondria-targeted TALEN (mito-TALENs). Our approaches represent a potential therapeutic avenue for preventing the transgenerational transmission of human mitochondrial diseases caused by mutations in mtDNA. PAPERCLIP.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25910206 PMCID: PMC4505837 DOI: 10.1016/j.cell.2015.03.051
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582